1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Competitive Analysis of the Global Opioid Therapeutics Market

  • October 2013
  • 64 pages
  • Frost & Sullivan
Report ID: 1863199

Summary

Table of Contents

Opportunities Exist for Tamper-resistant Formulations

This research service focuses on the current status of candidates for opioid therapeutics with a focus on current Phase 3 candidates, detailed timelines, rational for pivotal program design, Phase 2 data review and key opinion leader (KOL) commentary. A pipeline assessment is provided for all active candidates in development. The information contained in this research service was derived from published sources including the following: disease organization Web sites; Frost & Sullivan publications, including annual reports; Securities and Exchange Commission (SEC) filings and press releases; United States government public sources; and scientific journals.

Methodology and Scope

• This research service focuses on the global opioid therapeutics market with a focus on current Phase 3 candidates, detailed timelines, rational for pivotal program design, Phase 2 data review and key opinion leader (KOL) commentary.
• A pipeline assessment is provided for all active candidates in development.
• The information contained in this research service was derived from published sources including the following: Disease organization Web sites; Frost & Sullivan publications, including annual reports; Securities and Exchange Commission (SEC) filings and press releases; United States government public sources; and scientific journals.

Executive Summary

• Approximately X million Americans suffer from moderate-to-severe chronic pain that interferes with their daily lives.
• The current leader in the opioid therapeutics market is Purdue Pharma with its lead product, Oxycontin, estimated to generate $X billion in 2012 sales.
oEndo’s Lidoderm and Opana products generated $ billion in 2012 US sales.
oThe 3rd and 4th largest pain companies are Teva and Johnson & Johnson (J&J), respectively.
• There are X+ orally-delivered, marketed products with the majority of prescriptions for immediate-release generic opioids.
oBranded products—such as tamper-resistant formulations (TRFs)—that lack generic formulations continue to succeed in capturing significant market share.
• The pain therapeutics pipeline is dominated by TRFs, predominately because these new formulations are endorsed by the Food and Drug Administration (FDA), deter abuse, and enable previously genericized products to remain branded.
oThere areX+ TRF formulations in Phase 2 and later stages of development.

Regulatory Overview
In January 2013, the FDA issued a draft of abuse-deterrence study requirements for inclusion in product labeling.
• There is potential for pain-reducing drugs without TRF technology to be removed from the market, thus creating significant market opportunity for new TRF therapies to remain branded.
• New labeling is falls into X suggested tiers to describe abuse-deterrent properties including.
oFormulation with physicochemical barriers
oReduction/blockage of opioid effect when the product is manipulated
oMeaningful reduction in abuse
oDemonstrated reduced abuse in the community
• All safety categories will likely be required for all tiers, with Tier III requiring clinical abuse potential studies and Tier IV requiring post-marketing data.

Purdue Pharma
Purdue Pharma is the leader in the opioid therapeutics market with an estimated X percent of market share in 2012, led by Oxycontin.
• Oxycontin is Purdue’s oxycodone ER TRF, which holds an estimated % of total prescription share value or $X billion in US sales.
• Purdue Pharma also competes in the transdermal patch market with Butrans, which generated 2012 US sales of $X million.

Endo
Endo strongly competes both in the oral and transdermal patch markets.
• Endo’s flagship product, a transdermal patch, Lidoderm, generated $ billion in US sales. Generic competition is expected in 2014.
• Opana ER’s US sales were $ million in 2012, slipping from 2011 sales of $ million.

Pfizer
By 2020, Pfizer is projected to be the new leader in the pain market with a diverse portfolio including orally delivered, transdermal, and IV candidates.
• This is heavily dependant upon the success of their pipeline products.
• Remoxy was originally submitted for FDA approval in 2008; however, multiple setbacks persist due to FDA concerns regarding manufacturing of its tamper-resistant technology. Pfizer stated a development path forward is still active but has not provided details.
• Embeda is another Pfizer pain therapy with abuse-deterrence technology to suffer a setback as it was withdrawn from the market; however, re-launch could be expected by H1 2014.
• In June 2011, Pfizer gained approval for the first immediate release oxycodone designed to deter abuse, Oxecta; however, 2012 US sales were disappointing at approximately $X million.
• Pfizer also has a 3-day bupivacain transdermal patch in development which is expected to compete with J&J’s Duragesic.

J&J
J&J competes strongly both in the transdermal patch space and orals.
• Nucynta immediate release and extended-release (ER) formulations had combined US sales of $X million in 2012. J&J is currently conducting clinical trials to show the abuse-deterrence of Nucynta ER and plans to meet with the FDA in H2 2013—possibly providing a label update in 2014 or 2015.
• Ultram ER US sales peaked in 2008 with $Xmillion; however, 2012 sales have declined to $X million due to entry of generic competition.
• J&J’s transdermal patch generated 2012 US revenues of $ million.

Teva
Teva’s lead branded product is Fentora, which accounted for $X million in US revenues, but sales growth has been relatively flat since 2008—partly due to a dear doctors letters in 2007.
• Fentora is a effervescent tablet formulation of fentayl, launched to address cancer pain in 2006.
• Patent expiration is not until 2019, providing a wide opportunity for sales growth for other indications including breakthrough back pain, neuropathic pain, and non-cancer-related pain.
• Teva’s pain franchise is also supported by their generics division.

Nektar
Nektar currently has X products in their pipeline for pain.
• NKTR-181 is a mu-opioid analgesic in Phase 2 development—it is designed to reduce side effects such as respiratory depression, sedation, and abuse potential associated with conventional opioids.
• Nektar has plans to combine their novel mu-opioid analgesics with naloxegol, a Phase 3 candidate indicated to reduce opioid-induced constipation.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Acute Stress Disorder Global Clinical Trials Review, H1, 2017

  • $ 2500
  • Industry report
  • March 2017
  • by GlobalData

Acute Stress Disorder Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Acute Stress Disorder Global Clinical Trials Review, H1, 2017" provides an overview of Acute ...

Apnea Global Clinical Trials Review, H1, 2017

  • $ 2500
  • Industry report
  • March 2017
  • by GlobalData

Apnea Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Apnea Global Clinical Trials Review, H1, 2017" provides an overview of Apnea clinical trials scenario. This ...

Acute Pain Global Clinical Trials Review, H1, 2017

  • $ 2500
  • Industry report
  • February 2017
  • by GlobalData

Acute Pain Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Acute Pain Global Clinical Trials Review, H1, 2017” provides an overview of Acute Pain clinical trials ...


Download Unlimited Documents from Trusted Public Sources

Opioid Market

  • May 2017
    24 pages
  • Opioid  

View report >

HIV Antiviral Market and HIV AIDS Statistics

  • May 2017
    11 pages
  • HIV Antiviral  

    HIV AIDS  

  • United States  

    United Kingdom  

    Europe  

View report >

HIV Antiviral Market and HIV AIDS Statistics

  • May 2017
    9 pages
  • HIV Antiviral  

    HIV AIDS  

  • United Kingdom  

    United States  

    Europe  

View report >

Related Market Segments :

Opioid

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.